ClinicalTrials.gg
CompletedNCT01237223Updated Jun 13, 2012Results posted

Efficacy and Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension

A Phase 3 interventional study of Aliskiren/Amlodipine 150/2.5 mg and Aliskiren/amlodipine 150/5 mg in Essential Hypertension, sponsored by Novartis. Completed at 11 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2012-06-13.

Sponsored by Novartis · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,342
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 27 studies in Essential Hypertension by Novartis — none open to participants now, none under way, none of them phase 3. Essential Hypertension · Novartis.

Enrollment
3rd of 25
1,342 · median 506
Started
2010
with 5 others
Phase 3
15 of 27
none open now
Registered
17th of 27
by date

Among the 27 studies in Essential Hypertension by Novartis, this one is the 3rd largest by enrollment of the 25 interventional ones that give a count, is one of 6 that started in 2010, is one of 15 in phase 3, and was the 17th registered.

Essential Hypertension

481 studies on the registry are indexed under Essential Hypertension; 77 are open to participants now.

Browse Essential Hypertension studies →

Open to participants now

None of the 27 studies in Essential Hypertension by Novartis is open now. The open studies under Essential Hypertension, anywhere →

Who these studies take

Of the 45 Essential Hypertension studies recruiting now, 17 (38%) set no upper age limit and 20 (44%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 27 studies in Essential Hypertension by Novartis as a file.
02

Study summary

The purpose of the study was to evaluate the efficacy (blood pressure lowering effect) and safety of SPA100 (Fixed-dose Combination of Aliskiren and Amlodipine) in patients with essential hypertension (mean sitting diastolic blood pressure [msDBP] ≥ 95 mmHg and \< 110 mmHg and mean sitting systolic blood pressure [msSBP] ≥ 140 mmHg ). This study was conducted to support registration of the fixed-dose combination of aliskiren and amlodipine for the treatment of hypertension in Japan.

03

Conditions studied

  • Essential Hypertension

Keywords

  • Aliskiren
  • Amlodipine
  • Essential hypertension
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with essential hypertension (msDBP ≥ 95 mmHg and \< 110 mmHg and msSBP ≥140 mmHg )
  • Outpatients

Exclusion criteria

Exclusion Criteria:

  • Severe hypertension (msDBP ≥110 mmHg and/or msSBP ≥ 180 mmHg)
  • History of allergy or to renin inhibitors, calcium channel blockers
  • History or evidence of a secondary hypertension

Other protocol-defined inclusion/exclusion criteria applied

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
1,342 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study. In single blind run-in (4 weeks) and double blind treatment period (8 weeks), patients were received matching placebo of aliskiren/amlodipine 150/5 mg tablet, aliskiren/amlodipine 150/2.5 mg tablet, aliskiren 150 mg tablet and two amlodipine 2.5 mg capsules once daily.

    Drug: Placebo of Aliskiren · Drug: Placebo of Amlodipine · Drug: Placebo of Aliskiren/amlodipine 150/2.5 mg · Drug: Placebo of Aliskiren/amlodipine 150/5 mg

  • Active comparator
    Aliskiren 150 mg

    In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study. Patients received Aliskiren 150 mg tablet once daily (o.d)+ placebo of two amlodipine 2.5 mg capsule o.d., aliskiren/amlodipine 150/5 mg tablet o.d , aliskiren/amlodipine 150/2.5 mg tablet o.d for 8 weeks of double blind period.

    Drug: Aliskiren 150 mg · Drug: Placebo of Amlodipine · Drug: Placebo of Aliskiren/amlodipine 150/2.5 mg · Drug: Placebo of Aliskiren/amlodipine 150/5 mg

  • Active comparator
    Amlodipine 2.5 mg

    In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study. Patients received Amlodipine 2.5 mg capsule once daily (o.d)+ placebo of amlodipine 2.5 mg capsule o.d., Aliskiren 150 mg o.d., aliskiren/amlodipine 150/5 mg tablet o.d , aliskiren/amlodipine 150/2.5 mg tablet o.d for 8 weeks of double blind period.

    Drug: Amlodipine 2.5 mg · Drug: Placebo of Aliskiren · Drug: Placebo of Amlodipine · Drug: Placebo of Aliskiren/amlodipine 150/2.5 mg · Drug: Placebo of Aliskiren/amlodipine 150/5 mg

  • Active comparator
    Amlodipine 5 mg

    In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study. Patients received amlodipine 5 mg (two amlodipine 2.5 mg capsules o.d.)+ placebo of aliskiren 150 mg tablet o.d., aliskiren/amlodipine 150/5 mg tablet o.d. , aliskiren/amlodipine 150/2.5 mg tablet o.d. for 8 weeks of double blind period.

    Drug: Amlodipine 2.5 mg · Drug: Placebo of Aliskiren · Drug: Placebo of Aliskiren/amlodipine 150/2.5 mg · Drug: Placebo of Aliskiren/amlodipine 150/5 mg

  • Experimental
    Aliskiren/amlodipine 150/2.5 mg

    In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study. Patients received aliskiren/amlodipine 150/2.5 mg tablet o.d. + placebo of two amlodipine 2.5 mg capsules o.d., aliskiren 150 mg tablet o.d., aliskiren/amlodipine 150/5 mg tablet o.d. for 8 weeks of double blind period.

    Drug: Aliskiren/Amlodipine 150/2.5 mg · Drug: Placebo of Aliskiren · Drug: Placebo of Amlodipine · Drug: Placebo of Aliskiren/amlodipine 150/5 mg

  • Experimental
    Aliskiren/amlodipine 150/5 mg

    In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study. Patients received aliskiren/amlodipine 150/5 mg tablet o.d. + placebo of two amlodipine 2.5 mg capsules o.d., aliskiren 150 mg tablet o.d., aliskiren/amlodipine 150/2.5 mg tablet o.d. for 8 weeks of double blind period.

    Drug: Aliskiren/amlodipine 150/5 mg · Drug: Placebo of Aliskiren · Drug: Placebo of Amlodipine · Drug: Placebo of Aliskiren/amlodipine 150/2.5 mg

Interventions

  • DrugAliskiren/Amlodipine 150/2.5 mg

    Aliskiren/amlodipine 150/2.5 mg tablet

  • DrugAliskiren/amlodipine 150/5 mg

    Aliskiren/amlodipine 150/5 mg tablet

  • DrugAliskirenStudies of AliskirenAliskiren pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Aliskiren 150 mg tablet

  • DrugAmlodipineStudies of AmlodipineAmlodipine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Amlodipine 2.5 mg capsule

  • DrugPlacebo of Aliskiren

    Aliskiren placebo tablet

  • DrugPlacebo of Amlodipine

    Amlodipine placebo capsule

  • DrugPlacebo of Aliskiren/amlodipine 150/2.5 mg

    Aliskiren/amlodipine 150/2.5 mg placebo tablet

  • DrugPlacebo of Aliskiren/amlodipine 150/5 mg

    Aliskiren/amlodipine 150/5 mg placebo tablet

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) to End of Study (Week 8)

    Sitting blood pressure was measured at trough (24 hours ± 2 hours post dose) and recorded at all study visits. At the first study visit, blood pressure was measured in both arms and the arm with highest sitting DBP was found and used for all subsequent readings throughout the study. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these three sitting blood pressure measurements were used as the average sitting blood pressure for that visit. Analysis of covariance (ANCOVA) model contained treatment and region as two factors and baseline as a covariate.

    Time frame: Baseline, Week 8

Secondary outcomes

  1. Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) to End of Study (Week 8)

    Sitting blood pressure was measured at trough (24 hours ± 2 hours post dose) and recorded at all study visits. At the first study visit, blood pressure was measured in both arms and the arm with highest sitting DBP was found and used for all subsequent readings throughout the study. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these three sitting blood pressure measurements were used as the average sitting blood pressure for that visit. Analysis of covariance (ANCOVA) model contained treatment and region as two factors and baseline as a covariate.

    Time frame: Baseline, Week 8

  2. Percentage of Participants Achieving Blood Pressure Control at Endpoint

    Blood pressure control is defined as having as a msDBP \< 90 mmHg and a msSBP \< 140 mmHg.

    Time frame: 8 weeks

  3. Percentage of Participants Achieving a Successful Response Rate

    The response rate was defined as percentage of participants who achieved msDBP \< 90 mmHg or its reduction ≥ 10 mmHg from baseline to endpoint.

    Time frame: 8 weeks

  4. Number of Participants With Adverse Events, Serious Adverse Events and Death

    Number of patients with adverse events regardless of study drug relationship during the double-blind treatment period were reported. Serious adverse events of double blind period were reported.

    Time frame: 8 weeks

07

Results

Posted Jun 13, 2012

Participant flow

Single Blind(Run-in Period, 4 Weeks)
Participant flow — Single Blind(Run-in Period, 4 Weeks)
MilestonePlaceboAliskiren 150 mgAmlodipine 2.5 mgAmlodipine 5 mgAliskiren/Amlodipine 150/2.5 mgAliskiren/Amlodipine 150/5 mg
Started134200000
Completed94400000
Not completed39800000
Withdrew: Adverse event2900000
Withdrew: Abnormal laboratory value(s)2500000
Withdrew: Abnormal test procedure result(s)30800000
Withdrew: Subject withdrew consent2800000
Withdrew: Protocol deviation(s)800000
Double Blind (Treatment Period, 8 Weeks)
Participant flow — Double Blind (Treatment Period, 8 Weeks)
MilestonePlaceboAliskiren 150 mgAmlodipine 2.5 mgAmlodipine 5 mgAliskiren/Amlodipine 150/2.5 mgAliskiren/Amlodipine 150/5 mg
Started153157158158159159
Completed120142143153155154
Not completed331515545
Withdrew: Adverse event1243221
Withdrew: Unsatisfactory therapeutic effect2067101
Withdrew: Withdrawal by subject144011
Withdrew: Administrative problems000001
Withdrew: Protocol deviation(s)011211

Outcome measures

PrimaryChange From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) to End of Study (Week 8)

Sitting blood pressure was measured at trough (24 hours ± 2 hours post dose) and recorded at all study visits. At the first study visit, blood pressure was measured in both arms and the arm with highest sitting DBP was found and used for all subsequent readings throughout the study. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these three sitting blood pressure measurements were used as the average sitting blood pressure for that visit. Analysis of covariance (ANCOVA) model contained treatment and region as two factors and baseline as a covariate.

Time frame:
Baseline, Week 8
Reported as:
Least squares mean · mm Hg
Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) to End of Study (Week 8)
mm HgPlaceboAliskiren 150 mgAmlodipine 2.5 mgAmlodipine 5 mgAliskiren/Amlodipine 150/2.5 mgAliskiren/Amlodipine 150/5 mg
Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) to End of Study (Week 8)-5.21 ± 0.69-7.49 ± 0.68-9.46 ± 0.68-11.90 ± 0.68-12.40 ± 0.68-16.43 ± 0.68
SecondaryChange From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) to End of Study (Week 8)

Sitting blood pressure was measured at trough (24 hours ± 2 hours post dose) and recorded at all study visits. At the first study visit, blood pressure was measured in both arms and the arm with highest sitting DBP was found and used for all subsequent readings throughout the study. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these three sitting blood pressure measurements were used as the average sitting blood pressure for that visit. Analysis of covariance (ANCOVA) model contained treatment and region as two factors and baseline as a covariate.

Time frame:
Baseline, Week 8
Reported as:
Least squares mean · mm Hg
Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) to End of Study (Week 8)
mm HgPlaceboAliskiren 150 mgAmlodipine 2.5 mgAmlodipine 5 mgAliskiren/Amlodipine 150/2.5 mgAliskiren/Amlodipine 150/5 mg
Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) to End of Study (Week 8)-4.57 ± 0.97-10.63 ± 0.96-13.16 ± 0.96-17.98 ± 0.96-18.15 ± 0.96-25.49 ± 0.96
SecondaryPercentage of Participants Achieving Blood Pressure Control at Endpoint

Blood pressure control is defined as having as a msDBP \< 90 mmHg and a msSBP \< 140 mmHg.

Time frame:
8 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Blood Pressure Control at Endpoint
percentage of participantsPlaceboAliskiren 150 mgAmlodipine 2.5 mgAmlodipine 5 mgAliskiren/Amlodipine 150/2.5 mgAliskiren/Amlodipine 150/5 mg
Percentage of Participants Achieving Blood Pressure Control at Endpoint16.325.532.950.045.969.2
SecondaryPercentage of Participants Achieving a Successful Response Rate

The response rate was defined as percentage of participants who achieved msDBP \< 90 mmHg or its reduction ≥ 10 mmHg from baseline to endpoint.

Time frame:
8 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Successful Response Rate
percentage of participantsPlaceboAliskiren 150 mgAmlodipine 2.5 mgAmlodipine 5 mgAliskiren/Amlodipine 150/2.5 mgAliskiren/Amlodipine 150/5 mg
Percentage of Participants Achieving a Successful Response Rate34.646.550.670.365.486.2
SecondaryNumber of Participants With Adverse Events, Serious Adverse Events and Death

Number of patients with adverse events regardless of study drug relationship during the double-blind treatment period were reported. Serious adverse events of double blind period were reported.

Time frame:
8 weeks
Reported as:
Number · Participants
Number of Participants With Adverse Events, Serious Adverse Events and Death
ParticipantsPlaceboAliskiren 150 mgAmlodipine 2.5 mgAmlodipine 5 mgAliskiren/Amlodipine 150/2.5 mgAliskiren/Amlodipine 150/5 mg
Adverse Events625750495759
Serious Adverse Events002101
Death000000

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo (Double Blind)—0/153 (0%)21/153 (13.7%)
Aliskiren 150 mg—0/157 (0%)21/157 (13.4%)
Amlodipine 2.5 mg—2/158 (1.3%)17/158 (10.8%)
Amlodipine 5 mg—1/158 (0.6%)21/158 (13.3%)
Aliskiren/Amlodipine 150/2.5 mg—0/159 (0%)17/159 (10.7%)
Aliskiren/Amlodipine 150/5 mg—1/159 (0.6%)19/159 (11.9%)
Placebo (Single-Blind run-in Period)—4/1,342 (0.3%)136/1,342 (10.1%)
Most frequent serious events
Most frequent serious events
EventPlacebo (Double Blind)Aliskiren 150 mgAmlodipine 2.5 mgAmlodipine 5 mgAliskiren/Amlodipine 150/2.5 mgAliskiren/Amlodipine 150/5 mgPlacebo (Single-Blind run-in Period)
Gastric ulcerGastrointestinal disorders0/1530/1571/1580/1580/1590/1590/1342
Herpes zoster oticusInfections and infestations0/1530/1570/1581/1580/1590/1590/1342
PneumoniaInfections and infestations0/1530/1571/1580/1580/1590/1590/1342
Pelvic fractureInjury, poisoning and procedural complications0/1530/1570/1580/1580/1591/1590/1342
Hypertensive encephalopathyNervous system disorders0/1530/1570/1580/1580/1590/1591/1342
Putamen haemorrhageNervous system disorders0/1530/1570/1580/1580/1590/1591/1342
PneumothoraxRespiratory, thoracic and mediastinal disorders0/1530/1570/1580/1580/1590/1591/1342
Hypertensive crisisVascular disorders0/1530/1570/1580/1580/1590/1591/1342
Most frequent other events
Most frequent other events
EventPlacebo (Double Blind)Aliskiren 150 mgAmlodipine 2.5 mgAmlodipine 5 mgAliskiren/Amlodipine 150/2.5 mgAliskiren/Amlodipine 150/5 mgPlacebo (Single-Blind run-in Period)
NasopharyngitisInfections and infestations11/15317/15714/15819/15816/15916/15981/1342
HeadacheNervous system disorders12/1535/1573/1582/1581/1593/15959/1342

Baseline characteristics

Age Continuous
Age Continuous(years)PlaceboAliskiren 150 mgAmlodipine 2.5 mgAmlodipine 5 mgAliskiren/Amlodipine 150/2.5 mgAliskiren/Amlodipine 150/5 mgTotal
Mean54.6 ± 8.3555.0 ± 9.9654.8 ± 10.2555.8 ± 10.0554.6 ± 11.1155.5 ± 9.8655.1 ± 9.96
Age, Customized
Age, Customized(participants)PlaceboAliskiren 150 mgAmlodipine 2.5 mgAmlodipine 5 mgAliskiren/Amlodipine 150/2.5 mgAliskiren/Amlodipine 150/5 mgTotal
< 65 years128131129126125127766
>=65 years252629323432178
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboAliskiren 150 mgAmlodipine 2.5 mgAmlodipine 5 mgAliskiren/Amlodipine 150/2.5 mgAliskiren/Amlodipine 150/5 mgTotal
Female453945515157288
Male108118113107108102656
08

Study locations

11 sites
  • Investigative Site
    Aichi, Japan
  • Investigative Site
    Ehime, Japan
  • Investigative Site
    Fukuoka, Japan
  • Investigative Site
    Hokkaido, Japan
  • Investigative Site
    Hyogo, Japan
  • Investigative Site
    Kanagawa, Japan
  • Investigative Site
    Kyoto, Japan
  • Investigative Site
    Okayama, Japan
  • Investigative Site
    Osaka, Japan
  • Investigative Site
    Saitama, Japan
  • Investigative Site
    Tokyo, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2010, a primary completion of May 2011 and a completion of May 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2012, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2010
First posted
Nov 9, 2010
Start
Oct 2010
Primary completionActual
May 2011
CompletionActual
May 2011
Results first posted
Jun 13, 2012
Last update
Jun 13, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 13, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01237223
Lead sponsor
Novartis
Responsible party
Sponsor
First posted
Nov 9, 2010
Start date
Oct 2010
Primary completion
May 2011
Completion
May 2011
Results posted
Jun 13, 2012
Last update
Jun 13, 2012

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion